指南与共识胸部肿瘤乳腺癌

抗体药物偶联物在肺癌与乳腺癌中的应用:当前证据与未来方向——ETOP IBCSG Partners Foundation的立场声明

Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
指南 / 共识 · Ann Oncol · 2024-04-20

本立场声明由ETOP IBCSG Partners Foundation发布,总结抗体药物偶联物(ADC)在肺癌和乳腺癌中的当前证据与未来方向。目前已有14种ADC获批、逾100种在临床开发中;肺癌中T-DXd已获批用于HER2突变不可切除或转移性非小细胞肺癌,乳腺癌中已有曲妥珠单抗恩坦辛、T-DXd和SG等获批。声明强调亟需疗效与耐药生物标志物、治疗选择时活检及转化研究整合,并对ADC联合方案设定高门槛。

要点

  • 目前已有14种ADC获批、逾100种处于临床开发阶段。
  • 肺癌中T-DXd已获批用于HER2突变不可切除或转移性非小细胞肺癌。
  • 乳腺癌中曲妥珠单抗恩坦辛、T-DXd和SG等已获批并广泛使用。

核心结论

  • 随着可用ADC数量增加,亟需疗效与耐药生物标志物以更好选择患者。
  • 在治疗选择时采集活检样本并将转化研究纳入临床试验设计至关重要。
  • 对任何基于ADC的联合方案推进临床评价应设定高门槛,尤其考虑到高成本和潜在毒性影响。
  • 优化ADC剂量与疗程、序贯治疗及再挑战潜力也很重要,尤其需考虑可持续性方面。
  • ETOP IBCSG Partners Foundation正推动该领域合作并促进数据库、样本库和登记库的生成与共享。

研究设计与样本

  • 本文为ETOP IBCSG Partners Foundation发布的立场声明,总结肺癌和乳腺癌中ADC的当前证据与未来方向。

主要发现

  • 目前已有14种ADC获批、逾100种处于临床开发中。
  • 肺癌中T-DXd已获批用于HER2突变不可切除或转移性非小细胞肺癌,靶向HER3的patritumab deruxtecan、靶向滋养层细胞表面抗原2的datopotamab deruxtecan和sacituzumab govitecan(SG)、靶向间质上皮转化因子的telisotuzumab vedotin处于晚期临床开发中。
  • 乳腺癌中曲妥珠单抗恩坦辛、T-DXd和SG等多种药物已获批并广泛使用,多项晚期试验正在进行。
  • 在ADC治疗期间及治疗后采集的活检样本结合功能基因组学筛选,可能有助于了解应答与耐药机制以及ADC对肿瘤生物学和肿瘤微环境的影响。
  • 许多ADC正作为联合治疗接受评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in clinical development. In lung cancer, trastuzumab deruxtecan (T-DXd) is approved in human epidermal growth factor receptor 2 (HER2)-mutated, unresectable or metastatic non-small-cell lung cancer, with ADCs targeting HER3 (patritumab deruxtecan), trophoblast cell-surface antigen 2 [datopotamab deruxtecan and sacituzumab govitecan (SG)] and mesenchymal-epithelial transition factor (telisotuzumab vedotin) in late-stage clinical development. In breast cancer, several agents are already approved and widely used, including trastuzumab emtansine, T-DXd and SG, and multiple late-stage trials are ongoing. Thus, in the coming years, we are likely to see significant changes to treatment algorithms. As the number of available ADCs increases, biomarkers (of response and resistance) to better select patients are urgently needed. Biopsy sample collection at the time of treatment selection and incorporation of translational research into clinical trial designs are therefore critical. Biopsy samples taken peri- and post-ADC treatment combined with functional genomics screens could provide insights into response/resistance mechanisms as well as the impact of ADCs on tumour biology and the tumour microenvironment, which could improve understanding of the mechanisms underlying these complex molecules. Many ADCs are undergoing evaluation as combination therapy, but a high bar should be set to progress clinical evaluation of any ADC-based combination, particularly considering the high cost and potential toxicity implications. Efforts to optimise ADC dosing/duration, sequencing and the potential for ADC rechallenge are also important, especially considering sustainability aspects. The ETOP IBCSG Partners Foundation are driving strong collaborations in this field and promoting the generation/sharing of databases, repositories and registries to enable greater access to data. This will allow the most important research questions to be identified and prioritised, which will ultimately accelerate progress and help to improve patient outcomes.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Peters S, Loi S, André F, et al. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation. Ann Oncol. 2024. PMID: 38648979. doi:10.1016/j.annonc.2024.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。